Use of amifostine to ameliorate the toxic effects of chemotherapy in the treatment of cancer

Current Oncology

Volumn 7, Issue 3, 2000, Pages 149-161

  Vincent, M ^a   Bramwell, V ^a   Moran, L A ^a   Anderson, D ^a   Anderson, E ^a   Andriano, J ^a   Broadfield, L ^a   Campbell, C ^a   Charbonneau, F ^a   Feld, R ^a   Findlay, B ^a   Fine, S ^a   Harvey, S ^a   Iscoe, N ^a   Knight, G ^a   Major, P ^a   Moore, M ^a   Nefsky, M ^a   Palmer Wickham, S ^a   Poirier, S ^a   Puodziunas, A ^a   Rahim, Y ^a   Seymour, L ^a   Stewart, D ^a   Young, V ^a   more..

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MITOMYCIN C; PACLITAXEL;

ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; COOPERATION; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; HEALTH CARE COST; HUMAN; HYPOTENSION; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; PRACTICE GUIDELINE; QUALITY OF LIFE; SUBSTITUTION THERAPY; VERTIGO;

EID: 0033736058     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. A review of the use of chemoprotectants in cancer chemotherapy
2. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: Clinical experiences
3. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: A report of high response rates and prolonged survival
4. Guidelines for the administration of amifostine
5. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants
6. Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer
7. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: A randomised phase II study
8. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer
9. Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma
10. Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors
11. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group
12. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer
13. A phase III randomised trial of carboplatin and amifostine versus carboplatin and G-CSF in patients with inoperable non-small cell lung cancer (NSCLC)
14. Value of amifostine-cytoprotection in cisplatin and fluorouracil (5-FU) chemotherapy in head and neck cancer (HNCA). A randomized open-label trial
15. Amifostine (AM) in pediatric osteosarcoma (OS)
16. A randomised trial of the use of amifostine to reduce the side effects of chemotherapy with ifosfamide, carboplatin and etoposide (ICE) for small cell lung cancer (SCLC)
17. When was a 'negative' clinical trial big enough? How many patients you needed depends on what you found
18. Final report of the phase I trial of single-dose WR-2721 [S-2-(3-aminopropyl-amino)ethylphosphorothioic acid]
19. WR-2721 protects against the hematologic toxicity of cyclophosphamide: A controlled phase II trial
20. Influence of the cytoprotective agent amifostine (AMI) on pharmacokinetics (PK) of paclitaxel (PAC) and taxotere (TXT)
21. A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: An assessment of amifostine cytoprotection
22. Cost-utility assessment of amifostine in first-line therapy for ovarian cancer